Reviva Pharmaceuticals Holdings Inc — Balance Sheet (NASDAQ:RVPH) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Total assets 8.76 M31.4 M18.92 M23.7 M15.5 M Total liabilities 1.33 M2.72 M6.61 M17.98 M14.69 M Total equity 7.43 M28.69 M12.32 M5.72 M812.57 K Total liabilities & shareholders' equities 8.76 M31.4 M18.92 M23.7 M15.5 M Total debt ————— Net debt —————

News

Vocal biomarker study supports brilaroxazine’s efficacy in schizophrenia

Chardan Capital assumes coverage on Reviva Pharmaceuticals stock with Buy rating

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—12/30/25 - TipRanks.com

Reviva Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.16%

Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial

FDA recommends second phase 3 trial for Reviva’s schizophrenia drug

Dow Gains 100 Points; US Durable Goods Orders Decline In October - Argo Blockchain (NASDAQ:ARBK), Starfighters Space (AMEX:FJET)

US Stocks Mixed; GDP Growth Tops Expectations - Starfighters Space (AMEX:FJET), Highway Holdings (NASDAQ:HIHO)

FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva (RVPH): Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High

Reviva Pharmaceuticals' Schizophrenia Drug Hits Key Milestones During Third Quarter - Reviva Pharmaceuticals (NASDAQ:RVPH)